Announcement PDF Market Announcement 17 January 2024 Amplia Therapeutics Limited (ASX: ATX) – Trading Halt Description The securities of Amplia Therapeutics Limited (‘ATX’) will be placed in trading halt at the request of ATX, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Friday, 19 January 2024 or when the announcement is released to the market. Issued by ASX Compliance 17 January 2024 ASX Limited #10680798v1 Market Announcement 1/1 ASX Customer Service Centre 131 279 | asx.com.au ABN 16 165 160 841 17th Jan 2024 REQUEST FOR TRADING HALT Amplia Therapeutics Limited requests a Trading Halt in respect of the Company’s securities: • • • • The Trading Halt is requested as the Company has just received information in relation to its IND Application to the FDA; The Company expects that the Trading Halt will be required for up to 1 day The Company expects that the Trading Halt will be lifted upon release of an ASX announcement relating to its IND Application The Company is not aware of any reason why a Trading Halt should not be granted. Andrew J. Cooke Company Secretary About Amplia Therapeutics Limited Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on Twitter (@ampliatx), Threads (@ampliatx) and LinkedIn. Level 17, 350 Queen Street, Melbourne VIC 3000 Email info@ampliatx.com www.ampliatx.com